Patient-reported outcomes (PROs) in NRG Oncology RTOG 0436: a phase III trial evaluating the addition of cetuximab to paclitaxel, cisplatin, and radiation for esophageal cancer treated without surgery.
Lisa A KachnicKathryn WinterMohan SuntharalingamDavid IlsonAndré KonskiShane LloydSarah A McAvoyThomas LadOlugbenga Gbenga OlowokurePamela SamsonElizabeth M GoreJoshua E MeyerGregory M M VideticDavid A ClumpAdam RabenOmar KayalehJerry BarkerMichael G HaddockJudith O HopkinsDeborah W BrunerPublished in: Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation (2024)
The addition of cetuximab to CRT for the nonoperative management of esophageal cancer did not improve PROs.
Keyphrases
- phase iii
- patient reported outcomes
- open label
- metastatic colorectal cancer
- clinical trial
- minimally invasive
- phase ii
- locally advanced
- double blind
- coronary artery bypass
- wild type
- placebo controlled
- palliative care
- cardiac resynchronization therapy
- rectal cancer
- study protocol
- heart failure
- squamous cell carcinoma
- radiation therapy
- acute coronary syndrome